Apixaban
Also known as: ELIQUIS®
Use
Measurement of apixaban plasma concentration may be useful in select clinical situations such as concern about patient compliance, extremes of body weight, pregnancy, drug–drug interactions involving strong P‑glycoprotein and CYP3A4 inducers/inhibitors, perioperative management, thrombotic or hemorrhagic events, and renal or hepatic impairment.
Special Instructions
This assay is not indicated for routine therapeutic monitoring; samples should be collected at peak (3–4 hours after last dose). The assay uses a modified chromogenic anti‑Xa method; it is not specific for apixaban and will detect other anti‑Xa anticoagulants. Interfering conditions include gross lipemia, icterus, and hemolysis.
Limitations
Lower limit of detection approximately 30 ng/mL; trough levels may be below detection. The assay lacks specificity—other anti‑Xa agents (unfractionated heparin, LMWH, rivaroxaban, fondaparinux) will give measurable results. Universal therapeutic ranges are not established. Results may be affected by hemolysis, lipemia, or icterus.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided